Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes

HAYWARD, Calif., Sept. 17 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide. Building upon the successful completion of a 28-day phase 1b study of ITCA 650 in May of this year, the phase 2 study is intended to evaluate the doses achieving the best results in the phase 1b in a larger study population and for a longer duration of treatment. In addition, an extension phase of the phase 2 study will evaluate dose response of ITCA 650. Patients receiving Byetta for the first 12 weeks will be switched from Byetta to one of two doses of ITCA 650 to evaluate the potential for improving treatment effect.

"We are very pleased with the rapid progress and positive results achieved thus far in the ITCA 650 program" said Ken Luskey, MD, VP, Clinical Research for Intarcia. "In 2009, we expect to move the ITCA 650 program from IND-filing through completion of phase 2 enrollment."

"We have received strong interest in the ITCA 650 program since the late-breaker presentation of preliminary phase 1b study results at the American Diabetes Association Conference in June" said K. Alice Leung, President and CEO of Intarcia. "We intend to select a commercial partner for ITCA 650 prior to the start of phase 3 in the second half of 2010."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at human body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing clinical stage development programs for type 2 diabetes and hepatitis C.

SOURCE Intarcia Therapeutics, Inc.



CONTACT: James Ahlers of Intarcia Therapeutics, Inc., +1-510-782-7800

Web site: http://www.intarcia.com/

Back to news